Risk for Transmission of Naegleria fowleri From Solid Organ Transplantation

SL Roy, Centers for Disease Control and Prevention
R Metzger, TransLife Organ Procurement Organization
JG Chen, Arnold Palmer Hospital for Children
FR Laham, Arnold Palmer Hospital for Children
M Martin, Arnold Palmer Hospital for Children
SW Kipper, Sedgwick County Regional Forensic Science Center
LE Smith, Wesley Medical Center
George Lyon III, Emory University
J Haffner, Tampa General Hospital
JE Ross, Newberry Pathology Associates

Only first 10 authors above; see publication for full author list.

Final published version: http://dx.doi.org/10.1111/ajt.12536

Copyright information:
© 2013 The American Society of Transplantation and the American Society of Transplant Surgeons.

Accessed December 29, 2019 4:41 PM EST
Risk for Transmission of *Naegleria fowleri* from Solid Organ Transplantation

SL Roy¹, R Metzger²,³, JG Chen⁴, FR Laham⁴, M Martin⁴, SW Kipper⁵, LE Smith⁶, GM Lyon III⁷, J Haffner⁸, JE Ross⁹, AK Rye¹⁰, W Johnson¹¹, D Bodager¹¹, M Friedman¹¹, DJ Walsh¹¹, C Collins¹³, B Inman¹⁴, BJ Davis¹⁵, T Robinson¹⁶, C Paddock¹, SR Zaki¹, M Kuehnert¹, A DaSilva¹, Y Qvarnstrom¹, R Sriram¹, and GS Visvesvara¹

¹Centers for Disease Control and Prevention, Atlanta GA
²TransLife Organ Procurement Organization, Winter Park FL
³Florida Hospital Medical Center, Orlando FL
⁴Arnold Palmer Hospital for Children, Orlando FL
⁵Sedgwick County Regional Forensic Science Center, Wichita KS
⁶Wesley Medical Center, Wichita KS
⁷Emory University School of Medicine, Atlanta GA
⁸Tampa General Hospital, Tampa FL
⁹Newberry Pathology Associates, Newberry SC
¹⁰University of South Carolina School of Medicine, Columbia SC
¹¹Florida Department of Health, Tallahassee FL
¹²Orange County Health Department, Orlando FL
¹³Polk County Health Department, Bartow FL
¹⁴Brevard County Health Department, Viera FL
¹⁵Essentia Health, Duluth MN
¹⁶Minnesota Department of Health, St. Paul MN

Abstract

Primary amebic meningoencephalitis (PAM) caused by the free-living ameba *Naegleria fowleri* is a rare but rapidly fatal disease of the central nervous system (CNS) affecting predominantly young, previously healthy persons. No effective chemotherapeutic prophylaxis or treatment has been identified. Recently, three transplant-associated clusters of encephalitis caused by another
free-living ameba, *Balamuthia mandrillaris*, have occurred, prompting questions regarding the suitability of extra-CNS solid organ transplantation from donors with PAM. During 1995–2012, 21 transplant recipients of solid organs donated by five patients with fatal cases of PAM were reported in the United States. None of the recipients developed PAM and several recipients tested negative for *N. fowleri* by serology. However, historical PAM case reports and animal experiments with *N. fowleri*, combined with new post-mortem findings from four PAM patients, suggest that extra-CNS dissemination of *N. fowleri* can occur and might pose a risk for disease transmission via transplantation. The risks of transplantation with an organ possibly harboring *N. fowleri* should be carefully weighed for each individual recipient against the potentially greater risk of delaying transplantation while waiting for another suitable organ. In this article we present a case series and review existing data to inform such risk assessments.

**Keywords**

*Naegleria*; ameba; amoeba; primary amebic meningoencephalitis; disseminated; transplant

**Introduction**

*Naegleria fowleri* is a free-living ameba (FLA) inhabiting warm freshwater sites. It has also been isolated from soil (1). *N. fowleri* enters the body when contaminated water moves up the nose, such as during swimming or nasal irrigation (2). Amebae then cross the cribriform plate and reach the brain through the olfactory tract to cause primary amebic meningoencephalitis (PAM) (1) (Table 1). PAM progresses rapidly and has a mortality of approximately 99%, based on documented United States (US) cases. During 1962–2012, 128 PAM cases were reported in the US (3, CDC unpublished data); only one survived (4). Along with a second case from Mexico (5), these are the only well-documented survivors in North America through 2012.

PAM generally affects young, previously healthy individuals (3) who may be viewed as candidates for deceased-donor organ donation. Successful organ donations from three PAM patients have been reported (6–8). However, while no cases of *N. fowleri* transplant transmission have been documented thus far, the true risk is unknown. Transplant transmission of another FLA, *Balamuthia mandrillaris*, has been reported on three occasions (9–11), prompting questions about the potential risk for transplant transmission of *N. fowleri* and about the similarities and differences between these two amebae in terms of epidemiologic and clinical characteristics and diagnostic methods that might assist in recognizing and differentiating these cases to assist with management of recipients post-donation (Table 1). Consequently, the Centers for Disease Control and Prevention (CDC) has collaborated with attending physicians and pathologists to investigate possible *Naegleria* dissemination to organs outside the central nervous system (CNS). We summarize new pathology and laboratory data obtained from previously unreported PAM patients and new serology data from transplant recipients associated with PAM organ donors. Additionally, we review animal studies and historical human data suggestive of possible extra-CNS amebic dissemination, and discuss the potential risk for *N. fowleri* transmission through solid organ transplantation.
**Materials and Methods**

PAM diagnosis requires specialized laboratory testing only available in a few laboratories including CDC, which is consulted for diagnostic, clinical, and epidemiologic assistance by health professionals in the majority of reported PAM cases. The patients described herein represent all PAM cases during 2009–2012 for whom CDC provided laboratory testing and who either (1) donated organs or (2) underwent expanded autopsies with extra-CNS tissue testing. Clinical descriptions were compiled from reports from healthcare personnel; hospital, laboratory, and autopsy record reviews; and, in one patient, published literature. Laboratory tests performed at CDC are also summarized. Various methodologies are available at CDC to identify A. fowleri, including immunohistochemical techniques, culture, and a triplex real-time polymerase chain reaction (PCR) test. Immunohistochemical techniques, such as indirect immunofluorescence (IF) (12) and immune alkaline phosphatase (IHC) (13), use antibody specific for *N. fowleri* followed by microscopic examination to identify *N. fowleri* in tissue, culture, or cerebrospinal fluid (CSF). PCR testing can simultaneously identify and differentiate three meningoencephalitis-causing FLA (*N. fowleri*, *Acanthamoeba* spp., and *Balamuthia mandrillaris*) (14) and is used at CDC to diagnose and confirm PAM cases. An experimental immunofluorescence antibody (IFA) assay can detect serum antibodies to *N. fowleri* using an antibody competition assay. A positive serologic response is considered to be a titer of 1:128 or greater and indicates exposure to *N. fowleri* (4).

**Results**

**Case #1**

On August 14, 2009, a 10-year-old male was hospitalized in Florida with a 1-day history of meningitis-like symptoms (Table 2). He was given ceftriaxone, rifampin, and vancomycin for presumptive bacterial meningitis but later developed cough, shortness of breath, confusion, disorientation with hallucinations, and at least one grand mal seizure. A computed tomography (CT) brain scan without contrast on August 16 showed diffuse edema. Multiple organ system failure occurred and he died on August 17. Both kidneys were recovered and transplanted into two recipients.

On August 19, a post-mortem diagnosis of PAM was made when amebic trophozoites were observed in brain tissue at autopsy. CDC confirmed *N. fowleri* in the brain tissue by IIF; histopathology revealed deep parenchymal arterioles cuffed with trophozoites in the perivascular spaces. Autopsy specimens, including hematoxylin and eosin-stained (H&E) slides of pre-transplant kidney biopsies, were sent to CDC; no amebae were found in the kidneys. However, trophozoites were observed in H&E-stained sections of spleen, thyroid, lung, and heart; these tissues were also positive by IIF and IHC (Figure 1). Amebae observed in these organs were sparse; mostly in gaps, spaces, lumens, or along the periphery of tissues; frequently degraded; and generally not associated with tissue reaction, either inflammation or necrosis. The spleen showed fibro-congestive changes including polymorphonuclear leukocyte (PMN) infiltrates with numerous amebic antigens and degraded amebae along with a few whole amebae in the parenchyma on IIF, although only a few amebic particles and one whole ameba were seen on the periphery of the spleen by IHC.
Amebae were also observed on the edge and inside the parenchymal thyroid tissue by IIF and IHC. Some ameba in the lung sections were phagocytized by PMNs. Liver tissue tested negative for *N. fowleri* by IIF and IHC. All postmortem fresh tissue specimens obtained during autopsy were placed in cassettes and submerged in the same container of formalin before sectioning, potentially resulting in cross-contamination from the brain.

The kidney recipients were informed about these findings and followed closely for potential signs of organ rejection and PAM. One recipient had a kidney biopsy 1 year post-transplant per protocol, showing only mild fibrosis. The other recipient had diminished renal function with two biopsies to evaluate for possible rejection, at 9 months and 2.5 years post-transplant, both of which showed moderate fibrosis. Neither of the grafted kidneys showed evidence of *Naegleria* and, in August 2012, both recipients were well. Neither were tested for *N. fowleri* exposure or given anti-amebic chemotherapy.

**Case #2**

On September 18, 2009, a previously described 22-year-old male PAM patient in Florida, diagnosed pre-mortem, donated his kidneys, lungs, liver, heart, pancreas, and bowel to seven recipients (8). The pancreas/bowel recipient was alive and well in September 2011 and five other recipients were alive and well in March 2012. The right lung recipient died in August 2010 from recurrent disease unrelated to his transplant without evidence of PAM. None of the recipients received anti-amebic chemotherapy for *N. fowleri* exposure.

Approximately 2-years post-transplant, the liver recipient tested negative for *N. fowleri* antibodies with titers of 1:8 and lower. At this time, CDC obtained a small piece of banked heart tissue biopsied from the heart recipient approximately 1 month post-transplant; it tested negative for ameba by culture and Giemsa staining. Since then, multiple protocol biopsies of the heart have shown no evidence of rejection or other pathology and the heart recipient was alive and well in June 2012.

**Case #3**

On August 9, 2011, a 16-year-old female in Florida presented to an emergency room with a 3-day history of headache, fever, and vomiting. Electrolytes and blood counts were normal. She was treated with an intravenous (IV) fluid bolus and ceftriaxone, and discharged. On August 10, she was hospitalized with high fever, neck pain and stiffness, fatigue, and altered mental status. PAM was presumptively diagnosed because of motile amebae observed in her CSF and later confirmed by PCR and culture. PAM treatment was initiated with IV amphotericin B, azithromycin, fluconazole, and oral rifampin with dexamethasone for anticipated cerebral edema. Subsequently, she developed unequal pupils and progressive lethargy. On August 11, she was intubated and given hypertonic saline and mannitol. Intrathecal amphotericin B was administered through a lumbar spinal needle and a second CSF sample demonstrated the continued presence of motile ameba and progressive pleocytosis. On August 12, an external ventricular drain was placed and showed normal intracranial pressure. Intraventricular amphotericin B and IV chlorpromazine were administered. She deteriorated and died on August 13.
On August 14, her kidneys, lungs, liver, and pancreas were recovered and transplanted into four recipients. All recipients were alive and well in March 2012. One recipient with a bilateral lung transplant received treatment for possible Naegleria exposure with 2 days of IV Ambisome (August 14–16, 2011), which was stopped because of renal dysfunction; no further anti-amebic treatment was given. Approximately 7 weeks post-transplant, the four recipients provided serum for serologic testing of *N. fowleri* antibodies at CDC. All four tested negative with titers of 1:8 or lower.

**Case #4**

On August 19, 2011, a 14-year-old male in Kansas presented to hospital 1 day after illness onset. He was presumptively treated for meningitis with ceftriaxone, vancomycin, acyclovir, and mannitol. An MRI of the brain on August 20 was unremarkable. His symptoms progressed and he developed increased confusion, agitation, tonic-clonic activity, and had a seizure. He subsequently desaturated and was intubated. Tonsilar herniation of the brain occurred and he was pronounced dead on August 24. He was not an organ donor.

Post-mortem CSF tested positive for *N. fowleri* by PCR at CDC. CDC also received slides of brain, spinal cord, kidney, lung, liver, and heart from an expanded autopsy. Only CNS tissues tested positive for *N. fowleri* by IHC whereas CNS, kidney, and lung tissues tested positive by IIF, with many trophozoites and much antigenic debris observed in the kidney, and a few trophozoites with a little debris observed in both lungs. Six slides of kidney, lung, and liver tissues taken from patients with diseases other than PAM were also sent to CDC as controls—all tested negative by IIF. As with Case #1, cross-tissue contamination possibly occurred because all organs were sectioned using the same tools (rinsed between organs) and cassettes containing all organ specimens were placed in the same formalin-filled container prior to processing. However, in Case #4, the liver and heart, which were negative for *N. fowleri* by IHC and IIF, were also in this same container and placed in the same cassettes as extra-CNS tissues that tested positive (left lung and right lung, respectively).

**Case #5**

On July 15, 2012, an 8-year-old male from South Carolina was admitted to hospital 2 days after illness onset with presumptive meningitis and started on ceftriaxone and vancomycin. A head CT scan on July 16 showed diffuse subarachnoid hemorrhage within the basilar cisterns and layering along the tentorium with accompanying left parietal soft tissue swelling. The patient’s condition deteriorated requiring placement of an intracranial pressure (ICP) monitor. He became comatose with fixed, dilated pupils and was pronounced dead on July 17. He was not an organ donor.

A post-mortem diagnosis of PAM was made based on testing at CDC, including wet-mount observation of amebae in the CSF and positive CSF PCR and cultures. The patient underwent an expanded autopsy and tested positive for *N. fowleri* in extra-CNS tissues by PCR. As with Cases #1 and #4, histopathology results were difficult to interpret because autopsy tissues were potentially cross-contaminated when CNS and extra-CNS tissue specimens were preserved in the same formalin container. However, in this case, organs of the chest and abdomen were completely dissected and fresh unpreserved tissue specimens...
from these organs were collected and stored before the cranium was opened. These unpreserved tissues, collected before cross-contamination could occur, were sent to CDC for PCR. The brain, right lung, spleen, and intestine tested positive for *N. fowleri* by PCR while the kidney, heart, pancreas, and liver tested negative. Whether these positive PCR findings represented viable intact organisms in extra-CNS tissues or leakage of *Naegleria* debris across a compromised blood-brain barrier is unknown, but neither scenario could be ruled out. Further, it is unknown whether such leakage across the blood-brain barrier occurred pre-mortem or post-mortem.

**Case #6**

On August 4, 2012, a 9-year-old male from Minnesota was admitted to hospital 2 days after illness onset with apparent meningitis and started on ceftriaxone, vancomycin, acyclovir, dexamethasone, and mannitol. An unenhanced head CT on August 5 was unremarkable. The patient had progressive neurologic decline requiring intubation and ICP monitor placement. A presumptive pre-mortem diagnosis of PAM was made based on air dried Wright-stained CSF cytospin preparations. The patient was pronounced brain dead on August 6. He was not an organ donor.

An expanded autopsy was performed on August 7. The extra-CNS organs were removed and specimens were prepared for PCR testing at CDC before the cranium was opened, thereby ruling out possible cross-contamination from the CNS. The extra-CNS organs were grossly and microscopically normal. Intra-parenchymal tissues were sampled by avoiding organ surfaces, such as the pleura and liver capsule, and by using a visibly clean scalpel for tissue sectioning. The organ surfaces were not cauterized before sectioning and sterile scalpels and forceps were not used for handling tissue samples. CSF and olfactory and auditory nerve tissue tested positive for *N. fowleri* at CDC by PCR and culture, although serum antibody tests were negative at 1:2. Tissue specimens from the liver, heart, kidney, and pancreas tested negative for *N. fowleri* by PCR and culture. While lung tissue was also culture negative, it was reproducibly PCR positive. As with Case #5, it is unknown whether this PCR finding represented viable intact organisms or amebic debris in the lung. Further, it is unknown whether such leakage across the blood-brain barrier occurred pre-mortem or post-mortem.

**Discussion**

During 1995–2012, five known PAM patients in the US donated solid organs to 21 transplant recipients; three of the cases are described above (Cases #1, #2, #3) and two more have been described previously (6,7). None of these recipients are known to have developed PAM. Further, five recipients had negative *N. fowleri* serologies 7 weeks to 2 years post-transplant and one biopsy taken 1 month post-transplant from a donated heart tested negative for *N. fowleri*. However, there are data from human PAM cases and animal studies that challenge the assumption that *N. fowleri* is confined to the CNS. Since 2009, CDC has examined extra-CNS tissues from five PAM patients (Cases #1, 2, 4–6) and found evidence of varying strength to suggest extra-CNS dissemination of *Naegleria* might have occurred in four (Cases #1, 4–6) of the five cases.
In addition to these four cases, two PAM patients with possible extra-CNS dissemination of *Naegleria* have been previously reported. In 1943, an emaciated 22-year-old Japanese prisoner of war was treated pre-mortem for malaria and dysentery. On autopsy, amebae were observed by histology in his brain, lungs, stomach, small intestine, caecum, and mesenteric and gastric lymph nodes (1,15–17). In 1969, a 15-year-old female was diagnosed with PAM pre-mortem based motile amebae observed in her CSF (18,19). She received anti-amebic chemotherapy but developed acute diffuse myocarditis and pulmonary edema and died 5 days after symptom onset. On autopsy, tissues from multiple organs were obtained under aseptic conditions and cultured. Spleen, liver, and lung cultures were positive for *N. fowleri*, and an ameba was observed in the heart blood.

Extra-CNS dissemination of *Naegleria* has also been observed in multiple experiments involving mice (20–24). For example, histological examinations of mice given intranasal *Naegleria* inoculations demonstrated amebae invading the nasal mucosa by 36 hours post-inoculation, the olfactory nerve and anterior olfactory lobes by 72 hours, the cerebral hemispheres by 96 hours, and the lungs, liver, spleen, and renal capillaries by 108 hours (4.5 days) with death by 132 hours in most mice (20). In a similar experiment, occasional amebae were histologically observed in blood vessels in and around the olfactory bulbs and within the bone marrow and venous sinusoids of mice skulls at 96 hours after intranasal inoculation (21). At the same time, amebae were also cultured from blood and lung tissue. The researchers noted that *Naegleria* entered the blood stream of the CNS and bone marrow very late in the disease when tissue destruction was advanced, thin-walled veins were compromised, and mice were moribund.

Taken together, human and animal data suggest that hematogenous spread of *N. fowleri* to extra-CNS organs might be possible. The infectious dose of *N. fowleri* has not been established in humans but may be low; in one mouse experiment, the LD50 was 300 amebae but the lowest intranasal lethal dose was only 39 amebae (20). Although the infectious dose via solid organ transplantation is unknown, these data suggest a relatively few viable amebae may need to escape the CNS and contaminate a organ for transplant transmission to be possible. Experimental data from mouse models indicated that *Naegleria* escape the CNS late in the course of disease when tissue destruction is greatest and the blood-brain barrier is compromised. Therefore, although no cases of donor-derived organ transplant transmission of *N. fowleri* have been reported so far, the risk of such an occurrence is likely not zero.

Since 2009, solid organ transplant transmission of *Balamuthia*, a related free-living ameba (FLA), has been reported on three occasions (9–11). It is not fully understood why transplant transmission of *Balamuthia* has been documented but not that of *Naegleria* to date. One theory has been a difference temperature sensitivities. Unlike *Balamuthia*, *Naegleria* are known to be thermophilic (1). However, although *N. fowleri* trophozoites degenerate within hours at temperatures <10°C, the trophozoites encyst under adverse conditions and cysts capable of reforming viable trophozoites under more favorable conditions can survive for days to months at temperatures used for organ storage and transportation (25). Therefore, temperature sensitivities may not explain the difference in transplant transmission incidence between the two organisms. Another theory is that amebic transplant transmission may relate to length of infection in the donor, as implied by the
animal experiments previously described. Unlike *Naegleria, Balamuthia* causes a chronic infection and hence has the opportunity to hematogenously spread to other organs. Also unlike *Naegleria*, *Balamuthia* is known to spread hematogenously from extra-CNS sites to the CNS (26). Moreover, the recent clusters of transplant transmission confirm that hematogenous spread of *Balamuthia* occurs from the CNS to other organs as well. However, the data summarized in this report suggest that hematogenous spread from the CNS to other organs might also occur with *Naegleria*. Further exploration of the risk for hematogenous spread of *Naegleria* is required to better understand the risk and risk factors for such extra-CNS dissemination. Additionally, greater awareness of PAM among healthcare professionals involved in transplantation and inclusion of PAM in differential diagnoses during evaluations of potential donors with meningoencephalitis are needed. According to CDC surveillance data, only 25% of US PAM cases received a pre-mortem PAM diagnosis. Therefore, most PAM donors will be undiagnosed at the time of transplant.

To further define the risk of *N. fowleri* extra-CNS dissemination, full autopsies should be performed on PAM patients and any potential organ donor who dies with clinical signs or symptoms suggestive of meningitis or encephalitis. This practice would also help assess the risk of extra-CNS dissemination of other encephalitis-causing pathogens known to be transplant-transmitted, such as *Balamuthia mandrillaris*, rabies, and lymphocytic choriomeningitis virus (LCMV) (9–11,24,27). Full autopsies should include microscopic examinations of both CNS and extra-CNS tissues, particularly heart, lungs, liver, and kidneys. To minimize cross-contamination between CNS and extra-CNS tissues, examination and sampling of extra-CNS tissues and organs should be completed before removal of the brain. Ideally, separate workspaces and dissecting tools should be used to obtain CNS and extra-CNS tissues. Additionally, CNS and extra-CNS tissues should be placed in separate formalin containers and processed separately for paraffin embedding.

For guidance in recognizing CNS infections in potential deceased organ donors and for considerations during donor evaluation and organ offers, the Organ Procurement and Transplantation Network has provided information on their website at [http://optn.transplant.hrsa.gov/ContentDocuments/Guidance_DTAC_CNS_Infections_07-2012.pdf](http://optn.transplant.hrsa.gov/ContentDocuments/Guidance_DTAC_CNS_Infections_07-2012.pdf) (28). For assistance in diagnosing PAM, recommendations for *N. fowleri*-specific chemotherapy, and questions regarding transplant transmission of infectious diseases, CDC is available 24/7 by contacting the CDC Emergency Operations Center at 770-488-7100. Additionally, more information about the clinical features of PAM and its basic work-up is available on the CDC website at [http://www.cdc.gov/parasites/naegleria/health_professionals.html](http://www.cdc.gov/parasites/naegleria/health_professionals.html).

At present, no test is feasible for screening potential organ donors, no test has been approved for diagnostic use to detect organ recipient exposure or infection, no prophylactic chemotherapeutic regimen has been established, and no effective treatment regimen has been identified for amebic encephalitis (6). Although to date there is no evidence of *Naegleria* transplant transmission, the risk of transplantation with an organ possibly harboring *N. fowleri*, or other non-treatable agents of infectious encephalitis, should be carefully weighed for each individual recipient against the risk of delaying transplantation while waiting for another suitable organ.
Acknowledgments

The authors would like to acknowledge the contributions to case management, laboratory diagnosis, and information collection made by the following individuals:

- David Atrubin, MPH, Hillsborough County Health Department
- Becky Bandea, MS, M.ed, Centers for Disease Control and Prevention
- Theresa Benedict, BS, Centers for Disease Control and Prevention
- Aaron DeVries, MD, MPH, Minnesota Department of Health
- Eileen Farnon, MD, Centers for Disease Control and Prevention
- Beverly Keith, RN, BSN, Orange County Health Department
- Ruth Lynfield, MD, Minnesota Department of Health
- Warren McDougle, MPH, Hillsborough County Health Department
- David Overfield, BS, Orange County Health Department
- Geoffrey Witrak, MD, Essentia Health

Abbreviations

CDC  United States Centers for Disease Control and Prevention
CNS  central nervous system
CSF  cerebrospinal fluid
CT  computed tomography
FLA  free-living ameba
H&E  hematoxylin and eosin stain
IHC  immune alkaline phosphatase staining, a form of immunohistochemical testing
IIF  indirect immunofluorescence staining
IV  intravenous
PAM  primary amebic meningoencephalitis
PCR  polymerase chain reaction test
PMN  polymorphonuclear leukocyte
RBC  red blood cell
US  United States
WBC  white blood cell

References


Figure 1. Post-mortem examination of lung, thyroid, heart, and spleen tissue from a 10-year-old male organ donor in Florida (Case #1) who died from primary amebic meningoencephalitis due to *Naegleria fowleri* in 2009. *Naegleria fowleri* trophozoites in lung (upper left) and thyroid (upper right) sections by hematoxylin and eosin (H&E) staining at 1000X magnification. *Naegleria fowleri* trophozoites fluorescing in heart (lower left) and spleen (lower right) sections by indirect immunofluorescence (IIF) at 200X magnification.
Table 1
Epidemiologic and clinical summary of central nervous system disease caused by the free-living amebae *Naegleria fowleri* and *Balamuthia mandrillaris* in the United States

<table>
<thead>
<tr>
<th>Disease</th>
<th><em>Naegleria fowleri</em></th>
<th><em>Balamuthia mandrillaris</em></th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of reported cases (years)</td>
<td>128 (1962–2012)</td>
<td>85 (1974–2012)</td>
</tr>
<tr>
<td>Age</td>
<td>All ages but predominantly children (median 11 years, range 8 months–66 years)</td>
<td>All ages (median 35 years, range 8 months–89 years)</td>
</tr>
<tr>
<td>Sex</td>
<td>Males &gt;75% of reported cases</td>
<td>Males &gt;65% of reported cases</td>
</tr>
<tr>
<td>Ethnicity</td>
<td>No pattern discerned</td>
<td>More common among Hispanics</td>
</tr>
<tr>
<td>Immune status</td>
<td>Immunocompetent</td>
<td>Sometimes immunosuppressed</td>
</tr>
<tr>
<td>Exposure</td>
<td>Warm fresh water (recreational, potable)</td>
<td>Soil and dust, possibly fresh water</td>
</tr>
<tr>
<td>Geographic distribution</td>
<td>Historically southern-tier states but changing distribution to include northern states (Minnesota)</td>
<td>Across the United States</td>
</tr>
<tr>
<td>Seasonality</td>
<td>Summer with peak in July and August (range April–October)</td>
<td>Not apparent</td>
</tr>
<tr>
<td>Route of entry</td>
<td>Entry through the nose during recreational water activities or nasal irrigation with direct spread to brain through cribriform plate and olfactory tract</td>
<td>Entry through soil contamination of skin wounds or cuts or through inhalation of dust with hematogenous spread to the brain</td>
</tr>
<tr>
<td>Incubation period</td>
<td>Median 5 days (range 1–7 days)</td>
<td>Unknown—believed to be weeks or months; may be more rapid in transplant-transmission cases</td>
</tr>
<tr>
<td>Signs and symptoms</td>
<td>Acute onset of headache, fever, nausea, vomiting, stiff neck, seizures, altered mental status, hallucinations, coma</td>
<td>Subacute or chronic onset of headache, stiff neck, neck pain, photophobia, nausea, vomiting, altered mental status, behavioral changes, seizures, ataxia, focal neurologic deficits, impaired speech, weight loss; CNS symptoms may be preceded by one or more chronic skin lesions on face, trunk, or limbs appearing as nodules, ulcers, or abscesses</td>
</tr>
<tr>
<td>Differential diagnosis</td>
<td>Bacterial or viral meningitis</td>
<td>Brain tumor, lymphoma, stroke, vasculitis, abscess, TB or fungal meningoencephalitis, neurocysticercosis, toxoplasmosis, acute disseminated encephalomyelitis</td>
</tr>
<tr>
<td>Cerebrospinal fluid (CSF) parameters</td>
<td>Elevated opening pressure, polymophonuclear pleocytosis, normal or low glucose, elevated protein. Blood and/or motile amebae are suggestive of PAM</td>
<td>Normal or mildly elevated opening pressure, moderate lymphocytic pleocytosis, normal or low glucose, normal or elevated protein. Generally none to a few red blood cells. Amebae rarely observed</td>
</tr>
<tr>
<td>Brain imaging results</td>
<td>CT and MRI often normal early in disease, then may show cerebral edema with basilar meningoeal enhancement and obliteration of basilar cisterns; MRI might show one or more small enhancing round lesions in some cases</td>
<td>CT may show single or multiple hypodense, ring-enhancing, space-occupying lesions with occasional hemorrhage within lesions; MRI similar to CT but might be abnormal when CT is unremarkable</td>
</tr>
<tr>
<td>Laboratory confirmation</td>
<td>Amebae may be detected in CSF or tissue specimens</td>
<td>Amebae may be detected in tissue specimens</td>
</tr>
</tbody>
</table>

- Direct visualization of amebae with Giemsa-Wright or modified trichrome stains
- Polymerase chain reaction (PCR) testing for nucleic acid
- Immunohistochemistry to detect antigens

Serology for *N. fowleri* is currently considered a research technique and has not been evaluated for use as a routine diagnostic procedure.

Serology for *B. mandrillaris* is currently considered a research technique and has not been evaluated for use as a routine diagnostic procedure.
<table>
<thead>
<tr>
<th>Prognosis</th>
<th>Naegleria fowleri</th>
<th>Balamuthia mandrillaris</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mortality</td>
<td>Mortality &gt;99%</td>
<td>Mortality &gt;90%</td>
</tr>
<tr>
<td>Duration of illness from onset to death</td>
<td>Median 5 days (range 1–12 days)</td>
<td>Median 28 days (range 4–450 days)</td>
</tr>
<tr>
<td>Treatment</td>
<td>No effective treatment has been established; multiple medications used in combination</td>
<td>No effective treatment has been established; multiple medications used in combination</td>
</tr>
<tr>
<td>Organ donors and outcomes</td>
<td>During 1995–2012, five known PAM patients in the US donated solid organs to 21 transplant recipients, none of whom are known to have developed PAM. Further, five recipients had negative N. fowleri serologies and one biopsy from a donated heart tested negative for N. fowleri.</td>
<td>During 2009–2012, three known patients with granulomatous amebic encephalitis (GAE) due to Balamuthia in the US donated solid organs to 13 transplant recipients: four developed GAE and died, one developed GAE and survived with treatment, and six of the remaining eight recipients who did not develop Balamuthia GAE developed positive Balamuthia serologies.</td>
</tr>
</tbody>
</table>


3 CT = computed tomography; MRI = magnetic resonance imaging.


7 Diagnostic testing is not widely available for PAM. Clinicians who suspect PAM should contact their state health department and/or the CDC (24/7 Emergency Operation Center—770-488-1700). CDC can assist with diagnosis and provide treatment recommendations. Telediagnosis can be arranged at CDC by emailing photos through DPDx, CDC’s Division of Parasitic Diseases and Malaria telediagnosis tool. Instructions for submitting photos through DPDx are available at [http://www.dpd.cdc.gov/dpdx/HTML/Contactus.htm](http://www.dpd.cdc.gov/dpdx/HTML/Contactus.htm).

8 Detailed discussions of possible chemotherapeutic drug combinations can be found at [http://www.cdc.gov/parasites/naegleria/treatment-hcp.html](http://www.cdc.gov/parasites/naegleria/treatment-hcp.html) and [http://www.cdc.gov/parasites/balamuthia/treatment.html](http://www.cdc.gov/parasites/balamuthia/treatment.html). For 24/7 treatment recommendations, please contact the CDC Emergency Operation Center at 770-488-1700.

## Table 2

Case descriptions of referenced patients with primary amebic meningoencephalitis (PAM) due to *Naegleria fowleri*

<table>
<thead>
<tr>
<th>Case Number (Year and State)</th>
<th>Sex (Age in Years)</th>
<th>Exposure History</th>
<th>Presenting Symptoms and Signs</th>
<th>Initial Cerebrospinal Fluid (CSF) Test Results (Illness Day of Specimen Collection)</th>
<th>Diagnosis of PAM</th>
<th>Pre-Mortem <em>Naegleria fowleri</em> Specific Treatment</th>
<th>Expanded Autopsy</th>
<th>Organ Donation (Number of Recipients)</th>
</tr>
</thead>
</table>
| 1 (2009 Florida)            | Male (10)          | Swimming, jumping, inner tubing in a lake 6 days before symptom onset | Headache, vomiting, fever, neck stiffness, general malaise | • WBC 7,950 cells/mm³  
• RBC 40 cells/mm³  
• Protein 622 mg/dL  
• Glucose 1 mg/dL  
• Gram-negative diplococci  
• Bacterial cultures negative (collected on day 2 of 5) | Post-mortem diagnosis following transplant surgeries based on brain tissue IIF² | No | Yes | Kidneys (2) |
| 2² (2009 Florida)           | Male (22)          | Wakeboarding at a water sports arena 3 days before symptom onset | Headache, fever, neck pain, photosensitivity, positive Brudzinski and Kernig signs | • WBC 1,680 cells/mm³  
• RBC 263 cells/mm³  
• Protein 450 mg/dL  
• Glucose 42 mg/dL  
• Gram stain negative  
• Bacterial cultures negative  
• Amebae observed (collected on day 2 of 5) | Pre-mortem diagnosis based on motile ameba seen on CSF wet mount; diagnosis confirmed post-mortem by CSF PCR² and culture | Yes⁵ | No | Kidneys, liver, lungs, pancreas, heart, bowel (7) |
| 3 (2011 Florida)            | Female (16)        | Swimming and diving in a river 2 days before symptom onset | Headache, vomiting, fever, neck pain and stiffness, fatigue, altered mental status, a Glasgow Coma Scale score of 15, and non-focal | • WBC 4,180 cells/mm³  
• RBC 220 cells/mm³  
• Protein 362 mg/dL  
• Glucose 24 mg/dL | Pre-mortem diagnosis based on motile ameba seen on CSF wet mount; diagnosis confirmed post-mortem by CSF PCR and culture | Yes⁶ | No | Kidneys, liver, lungs, pancreas (4) |
<table>
<thead>
<tr>
<th>Case Number (Year and State)</th>
<th>Sex (Age in Years)</th>
<th>Exposure History</th>
<th>Presenting Symptoms and Signs</th>
<th>Initial Cerebrospinal Fluid (CSF) Test Results (Illness Day of Specimen Collection)</th>
<th>Diagnosis of PAM</th>
<th>Pre-Mortem Naegleria fowleri-Specific Treatment</th>
<th>Expanded Autopsy</th>
<th>Organ Donation (Number of Recipients)</th>
</tr>
</thead>
<tbody>
<tr>
<td>4 (2011 Kansas) Male (14)</td>
<td>Swimming and splashing in a lake 4 and 5 days before symptom onset</td>
<td>Headache, nausea, decreased oral intake, fever, neck stiffness, photophobia, confusion</td>
<td>WBC 1,000 cells/mm³</td>
<td>RBC 200 cells/mm³</td>
<td>Protein 151 mg/dL</td>
<td>Glucose 46 mg/dL (collected on day 2 of 7)</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>5 (2012 South Carolina) Male (8)</td>
<td>Diving, swimming, and tubing in a lake, pond, ocean, and pool on multiple occasions within the 7 days before symptom onset</td>
<td>Headache, vomiting, abdominal pain, fever, lethargy</td>
<td>WBC 10,113 cells/mm³</td>
<td>RBC 27 cells/mm³</td>
<td>Protein 390 mg/dL</td>
<td>Glucose 8 mg/dL (collected on day 4 of 5)</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>6 (2012 Minnesota) Male (9)</td>
<td>Swam in multiple fresh water sites, including lake 1 day before symptom onset</td>
<td>Headache, vomiting, fever, lethargy, confusion, blurred vision, diplopia</td>
<td>WBC 1,463 cells/mm³</td>
<td>RBC 228 cells/mm³</td>
<td>Protein 411 mg/dL</td>
<td>Glucose 68 mg/dL</td>
<td>Bacterial cultures positive for coagulase-negative Staphylococcus species</td>
<td>Amebae observed (Collected on day 4 of 6)</td>
</tr>
</tbody>
</table>
All patients were previously healthy and had no significant past medical history.

In indirect immunofluorescence specific for *Naegleria fowleri*.


PCR = triplex real-time polymerase chain reaction specific for *Naegleria fowleri*.

Pre-mortem treatment for *N. fowleri* included amphotericin B (intravenous and intraventricular), rifampin, azithromycin, and fluconazole.

Pre-mortem treatment for *N. fowleri* included amphotericin B (intravenous and intraventricular), rifampin, azithromycin, fluconazole, and chlorpromazine.